Credit: Shutterstock
December 19, 2023 11:24 AM ESTUpdated December 20, 03:14 PM
R&D
In Focus

Lil­ly, No­vo’s bet on heart dis­ease starts to take shape, and 2024 could be a piv­otal year for their GLP-1s 

Max Gelman

Senior Editor

Eli Lil­ly and No­vo Nordisk are steadi­ly — and some­what qui­et­ly — prepar­ing to build com­pre­hen­sive car­dio­vas­cu­lar fran­chis­es helmed by their lu­cra­tive treat­ments for di­a­betes and obe­si­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times